NRX Pharmaceuticals, Inc. Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount
NRX Pharmaceuticals, Inc. (NRXP) reported Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount · last filed 2025-03-14
- NRX Pharmaceuticals, Inc. warrant down round feature decrease in net income loss to common shareholder amount for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- NRX Pharmaceuticals, Inc. warrant down round feature decrease in net income loss to common shareholder amount for fiscal 2023 was $9.00K.
| Period end | Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount 12 month |
|---|---|
| 2024-12-31 | $0.00 10-K · filed 2025-03-14 |
| 2023-12-31 | $9.00K 10-K · filed 2025-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |
| INOVIO PHARMACEUTICALS, INC. (INO) | United States | $0.125B | -1.35 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| Aardvark Therapeutics, Inc. (AARD) | United States | $0.121B | -1.80 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| CUMBERLAND PHARMACEUTICALS INC (CPIX) | United States | $0.121B | -8.95 |